Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004-2006

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 8, 2007, Pages 889-907

  Huang, Yiyun ^a   Williams, Wendol A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT1A; 5 HT1B; Antidepressant; Depression; Neurokinin receptor; NK1 antagonist; Noradrenaline re uptake inhibitor; Selective serotonin re uptake inhibitor; Serotonin transporter; Substance P

Indexed keywords

3 AMINO 1 ARYLPROPYLINDOLE DERIVATIVE; 3 AMINOCHROMAN DERIVATIVE; 3 AMINOPYRROLIDINE DERIVATIVE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ANTIDEPRESSANT AGENT; BENZODIOXAN DERIVATIVE; BENZOFURANYLPIPERAZINEQUINOLINE DERIVATIVE; BENZOTHIENYLPIPERAZINEQUINOLINE DERIVATIVE; BETA LACTAM DERIVATIVE; CITALOPRAM; DIAZACYCLOOCTANE DERIVATIVE; DULOXETINE; GLYCINAMIDE; IMIPRAMINE; INDOLALKYLPIPERAZINE DERIVATIVE; MONOAMINE REUPTAKE INHIBITOR; MORPHOLINE DERIVATIVE; N PYRROLIDIN 3 YLAMIDE DERIVATIVE; NEUROKININ 1 RECEPTOR ANTAGONIST; NISOXETINE; PYROVALERONE DERIVATIVE; PYRROLIDINEAMINE DERIVATIVE; QUINOLINE 3 AMINOCHROMAN DERIVATIVE; REBOXETINE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

BINDING AFFINITY; CHEMICAL MODIFICATION; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

EID: 34548295512     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.8.889     Document Type: Review

References (106)

1. KESSLER RC, AKISKAL HS, AMES M et al.: Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am. J. Psychiatry (2006) 163(9):1561-1568.
2. USTUN TB, AYUSO-MATEOS JL, CHATTERJI S, MATHERS C, MURRAY CJ: Global burden of depressive disorders in the year 2000. Br. J. Psychiatry (2004) 184:386-392.
3. ANDRADE L, CARAVEO-ANDUAGA JJ, BERGLUND P et al.: The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int. J. Methods Psychiatry Res. (2003) 12(1):3-21.
4. KESSLER RC, BERGLUND P, DEMLER O et al.: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 289(23):3095-3105.
5. KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51(1):8-19.
6. STEWART WF, RICCI JA, CHEE E, HAHN SR, MORGANSTEIN D: Cost of lost productive work time among US workers with depression. JAMA (2003) 289(23):3135-3144.
7. GREENBERG PE, BIRNBAUM HG: The economic burden of depression in the US: societal and patient perspectives. Expert Opin. Pharmacother. (2005) 6(3):369-376.
8. GREENBERG PE, KESSLER RC, BIRNBAUM HG et al.: The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry (2003) 64(12):1465-1475.
9. HYTTEL J: Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Pychopharmacol. (1994) 9(Suppl. 1):19-26.
10. ARTIGAS F: 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol. Sci. (1993) 14(7):262.
11. MACE S, TAYLOR D: Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin. Pharmacother. (2000) 1(5):917-933.
12. BRINER K, DODEL RC: New approaches to rapid onset antidepressants. Curr. Pharm. Des. (1998) 4(4):291-302.
13. ROSEN RC, LANE RM, MENZA M: Effects of SSRIs on sexual function: a critical review. J. Clin. Pychopharmacol. (1999) 19(1):67-85.
14. STAHL SM: Essential psychopharmacology: neuroscientific basis and practical applications. 2nd Edition, New York: Cambridge University Press (2004).
15. ARTIGAS F, NUTT DJ, SHELTON R: Mechanism of action of antidepressants. Psychapharmacol. Bull. (2002) 36(Suppl. 2):123-132.
16. BYMASTER FP, LEE TC, KNADLER MP, DETKE MJ, IYENGAR S: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharm. Des. (2005) 11(12):1475-1493.
17. SHELTON C, ENTSUAH R, PADMANABHAN SK, VINALL PE: Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int. Clin. Pychopharmacol. (2005) 20(4):233-238.
18. BOOT J, CASES M, CLARK BP et al.: Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/ norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(3):699-703.
19. BOOT JR, BOULET SL, CLARK BP et al.: N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg. Med. Chem. Lett. (2006) 16(10):2714-2718.
20. BOOT JR, BRACE G, DELATOUR CL et al.: Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg. Med. Chem. Lett. (2004) 14(21):5395-5399.
21. FISH PV, FRAY MJ, STOBIE A, WAKENHUT F, WHITLOCK GA: N-Benzyl-N-(tetrahydro-2H-pyran-4-yl) pyrrolidin-3-amines as selective dual serotonin/noradrenaline re-uptake inhibitors. Bioorg. Med. Chem. Lett. (2007) 17(7):2022-2025.
22. FRAY MJ, BISH G, BROWN AD et al.: N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/ noradrenaline reuptake inhibitor. Bioorg. Med. Chem. Lett. (2006) 16(16):4345-4348.
23. FRAY MJ, BISH G, FISH PV et al.: Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Biborg. Med. Chem. Lett. (2006) 16(16):4349-4353.
24. ORJALES A, MOSQUERA R, TOLEDO A et al.: Syntheses and binding studies of new [(aryl)(aryloxy)methyl]-piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters. J. Med. Chem. (2003) 46(25):5512-5532.
25. STAHL SM: Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. (1998) 51(3):215-235.
26. BLIER P, PINEYRO G, EL MANSARI M, BERGERON R, DE MONTIGNY C: Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann. NY Acad. Sci. (1998) 861:204-216.
27. 1A antagonists. Trends Neurosci. (1996) 19(9):378-383.
28. 1A receptors induces rapid antidepressant response. Neuropsychopharmacology (1997) 16(5):333-338.
29. ADELL A, CASTRO E, CELADA P et al.: Strategies for producing faster acting antidepressants. Drug Discov. Today (2005) 10(8):578-585.
30. ARTIGAS F, ADELL A, CELADA P: Pindolol augmentation of antidepressant response. Curr. Drug Targets (2006) 7(2):139-147.
31. ARTIGAS F, PEREZ V, ALVAREZ E: Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry (1994) 51(3):248-251.
32. PEREZ V, GILABERTE I, FARIES D, ALVAREZ E, ARTIGAS F: Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet (1997) 349(9065):1594-1597.
33. 11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology (2001) 24(3):209-229.
34. RABINER EA, BRAGWAGAR Z, GUNN RN et al.: Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J. Psychiatry (2001) 158(12):2080-2082.
35. SOKOLSKI KN, CONNEY JC, BROWN BJ, DEMET EM: Once-daily high-dose pindolol for SSRI-refractory depression. Psychiatry Res. (2004) 125(2):81-86.
36. 1A receptor. Bioorg. Med. Chem. Lett. (2005) 15(4):911-914.
37. 1A receptor and serotonin transporter affinity. Bioorg. Med. Chem. Lett. (2006) 16(5):1338-1341.
38. 1A receptor and serotonin transporter affinity. J. Med. Chem. (2006) 49(15):4785-4789.
39. 1A receptor antagonism/SSRI activities. Part 4. Bioorg. Med. Chem. Lett. (2004) 14(10):2653-2656.
40. 1A receptor antagonism/SSRI activities. Part 3. Bioorg. Med. Chem. Lett. (2003) 13(22):3939-3942.
41. 1A receptor antagonism/SSRI activities. Part 5. Bioorg. Med. Chem. Lett. (2006) 16(9):2347-2351.
42. 1A receptor antagonism/SSRI activities. Part 2. Bioorg. Med. Chem. Lett. (2003) 13(14):2393-2397.
43. 1A receptor antagonism/SSRI activities. Part 1. Bioorg. Med. Chem. Lett. (2003) 13(11):1903-1905.
44. BLIER P: Pharmacology of rapid-onset antidepressant treatment strategies. J. Clin. Psychiatry (2001) 62(Suppl. 15):12-17.
45. HJORTH S, BENGTSSON HJ, KULLBERG A et al.: Serotonin autoreceptor function and antidepressant drug action. J. Psychopharmacol. (2000) 14(2):177-185.
46. 1B receptor antagonist with negative intrinsic activity. Br. J. Pharmacol. (1998) 125(1):202-208.
47. 1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2, 3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity. Neuropharmacology (2006) 50(8):975-983.
48. 1B/1D receptor antagonists and agonists and their potential therapeutic applications. Curr. Top Med. Chem. (2002) 2(6):559-574.
49. ROBERTS C, PRICE GW, MIDDLEMISS DN: Ligands for the investigation of 5-HT autoreceptor function. Brain Res. Bull. (2001) 56(5):463-469.
50. 1B receptor antagonist. Neuropharmacology (2006) 50(8):984-990.
51. 1B autoreceptor antagonist. Eur. J. Pharmacol. (2004) 499(1-2):67-75.
52. 1B/1D antagonists: chemistry and pharmacological evaluation of N-piperazinylphenyl biphenylcarboxamides and biphenylsulfonamides. J. Med. Chem. (2000) 43(3):517-525.
53. 1D antagonist and a 5-HT reuptake inhibitor synergistically, Increases 5-HT release in guinea pig hypothalamus in vivo. J. Neurochem. (1996) 67(5):2204-2207.
54. 1B/1D antagonists with paroxetine on serotonin efflux in rat ventral lateral geniculate nucleus slices. Brain Res. Bull. (1997) 43(4):405-409.
55. 1B autoreceptors induced by fluoxetine in rat frontal cortex. Nauryn Schmiedebergs Arch. Pharmacol. (2004) 370(2):84-90.
56. 1B knockout mice. Neuropsychopharmacology (2003) 28(5):850-856.
57. 1B autoreceptors in the enhancement of serotonin turnover in the mouse brain following repeated treatment with fluoxetine. Life Sci. (2002) 71(24):2867-2880.
58. 1B receptor selectivity for 5-HT terminal autoreceptor activity: an in vivo microdialysis study in the freely-moving guinea-pig. Neuropharmacology (1997) 36(4-5):549-557.
59. 1B/1D receptors in the modulation of 5-hydroxytryptamine levels in the frontal cortex of the conscious guinea pig. Eur. J. Pharmacol. (1997) 326(1):23-30.
60. JONGSMA ME, BOSKER FJ, CREMERS TI, WESTERINK BH, DEN BOER JA: The effect of chronic selective serotonin reuptake inhibitor treatment on serotonin 1B receptor sensitivity and HPA axis activity. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29(5):738-744.
61. MORET C: Depression: emerging research and treatment approaches. 16-17 January 2003, Paris, France. IDrugs (2003) 6(3):183-186.
62. 1B/1D antagonistic activity: a new approach toward efficient antidepressants. J. Med. Chem. (2000) 43(6):1149-1157.
63. 1D antagonist/serotonin reuptake inhibitor lead using rapid parallel synthesis. Bioorg. Med. Chem. Lett. (2004) 14(10):2469-2472.
64. KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281(5383):1640-1645.
65. ARGYROPOULOS SV, NUTT DJ: Substance P antagonists: novel agents in the treatment of depression. Expert Opin. Investig. Drugs (2000) 9(8):1871-1875.
66. 1 receptor) antagonists. Curr. Opin. Investig. Drugs (2002) 3(2):257-261.
67. EBNER K, RUPNIAK NM, SARIA A, SINGEWALD N: Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. USA (2004) 101(12):4280-4285.
68. MAENO H, KIYAMA H, TOHYAMA M: Distribution of the substance P receptor (NK-1 receptor) in the central nervous system. Brain Res. Mol. Brain Res. (1993) 18(1-2):43-58.
69. 3 binding sites. Neuroscience (2003) 116(3):761-773.
70. ADELL A: Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms? Curr. Drug Targets CNS Neurol. Disord. (2004) 3(2):113-121.
71. SERGEYEV V, HOKFELT T, HURD Y: Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport (1999) 10(18):3967-3970.
72. STOUT SC, OWENS MJ, NEMEROFF CB: Neurokinin1 receptor antagonists as potential antidepressants. Ann. Rev. Pharmacol. Toxicol. (2001) 41:877-906.
73. CULMAN J, KLEE S, OHLENDORF C, UNGER T: Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J. Pharmacol. Exp. Ther. (1997) 280(1):238-246.
74. 1) receptor antagonist in major depression. Neuropsychopharmacology (2004) 29(2):385-392.
75. 1 receptor have a role in depression and anxiety? Curr. Pharm. Des. (2005) 11(12):1529-1547.
76. BLIER P, GOBBI G, HADDJERI N et al.: Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J. Psychiatry Neurosci. (2004) 29(3):208-218.
77. 1A autoreceptors in mice. J. Neurochem. (2005) 95(6):1713-1723.
78. CONLEY RK, CUMBERBATCH MJ, MASON GS et al.: Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J. Neurosci. (2002) 22(17):7730-7736.
79. 1A ]autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensidzation. J. Neurosci. (2001) 21(20):8188-8197.
80. HADDJERI N, BLIER P: Sustained blockade of neurokinin-1 receptors enhances serotonin neuroutransmission. Biol. Psychiatry (2001) 50(3):191-199.
81. SANTARELLI L, GOBBI G, DEBS PC et al.: Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and, Increases serotonergic function. Proc. Natl. Acad. Sci. USA (2001) 98(4):1912-1917.
82. GUIARD BP, LANFUMEY L, GARDIER AM: Microdialysis approach to study serotonin outflow in mice following selective serotonin reuptake inhibitors and substance P (neurokinin 1) receptor antagonist administration: a review. Curr. Drug Targets (2006) 7(2):187-201.
83. GULARD BP, PRZYBYLSKI C, GUILLOUX JP et al.: Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J. Neurochem. (2004) 89(1):54-63.
84. 1 receptor antagonist in the mouse forced swimming test. Behav. Brain Res. (2006) 172(2):256-263.
85. 1 antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants. Bioorg. Med. Chem. Lett. (2002) 12(2):261-264.
86. 1 antagonists - serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives. Bioorg. Med. Chem. Lett. (2002) 12(21):3195-3198.
87. 1B receptor function by p11 in depression-like states. Science (2006) 311(5757):77-80.
88. SVENNINGSSON P, GREENGARD P: p11(S100A10) - an inducible adaptor protein that modulates neuronal functions. Curr. Opin. Pharmacol. (2007) 7(1):27-32.
89. BROOKS DJ: Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx (2005) 2(2):226-236.
90. LEE CM, FARDE L: Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol. Sci. (2006) 27(6):310-316.
91. TALBOT PS, LARUELLE M: The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur. Neuropsychopharmacol. (2002) 12(6):503-511.
92. WANG J, MAURER L: Positron ermission tomography: applications in drug discovery and drug development. Curr. Top Med. Chem. (2005) 5(11):1053-1075.
93. 11C]vinpocetine in human subjects. Acta Neurol. Scand. (2002) 106(6):325-332.
94. GULYAS B, HALLDIN C, SOVAGO J et al.: Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprorective drug vinpocetine. Eur. J. Nucl. Med. Mol. Imaging (2002) 29(8):1031-1038.
95. 11C]AFM. J. Cereb. Blood Flow Metab. (2002) 22(11):1377-1398.
96. 11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. Nucl. Med. Biol. (2004) 31(8):983-994.
97. 11C]WAY-100635. Eur. J. Pharmacol. (1996) 301(1-3):R5-R7.
98. 11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology (2001) 24(3):209-229.
99. 11C]DASB PET imaging study. Am. J. Psychiatry (2001) 158(11):1843-1849.
100. 11C]DASB positron emission tomography study. Am. J. Psychiatry (2004) 161(5):826-835.
101. SUHARA T, TAKANO A, SUDO Y et al.: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch. Gen. Psychiatry (2003) 60(4):386-391.
102. TAKANO A, SUZUKI K, KOSAKA J et al.: A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl.) (2006) 185(3):395-399.
103. DING YS, FOWLER J: New-generation radiotracers for nAChR and NET. Nucl. Med. Biol. (2005) 32(7):707-718.
104. 2. Psychopharmacology (Berl.) (2006) 188(1):119-127.
105. 1) in the living human brain using positron emission tomography. J. Clin. Psychiatry (2002) 63(Suppl. 11):18-24.
106. BERGSTROM M, HARGREAVES RJ, BURNS HD et al.: Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry (2004) 55(10):1007-1012.